Advertisement

Topics

Latest "Daiichi Sankyo takes option diabetes stem cell start" News Stories

05:11 EDT 23rd March 2019 | BioPortfolio

Here are the most relevant search results for "Daiichi Sankyo takes option diabetes stem cell start" found in our extensive news archives from over 250 global news sources.

More Information about Daiichi Sankyo takes option diabetes stem cell start on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Daiichi Sankyo takes option diabetes stem cell start for you to read. Along with our medical data and news we also list Daiichi Sankyo takes option diabetes stem cell start Clinical Trials, which are updated daily. BioPortfolio also has a large database of Daiichi Sankyo takes option diabetes stem cell start Companies for you to search.

Showing "Daiichi Sankyo takes option diabetes stem cell start" News Articles 1–25 of 20,000+

Saturday 23rd March 2019

Author Correction: Adrenergic nerve degeneration in bone marrow drives aging of the hematopoietic stem cell niche


Simple start for complex products

Abbisko Completes $42 Million Series B Funding for Oncology Candidates

Abbisko Therapeutics of Shanghai completed a $42 million series B fundraising led by new investor Qiming, which it will use to start clinical trials of its oncology molecules and expand its discovery pipeline. Later this year, the company expects to start Phase I trials of its two lead candidates, a small molecule FGFR4 inhibitor for hepatocellular carcinoma (HCC) and a CSF1R inhibitor for solid t...


Friday 22nd March 2019

CRISPR/Cas9-modified hematopoietic stem cells—present and future perspectives for stem cell transplantation

Incidence and predictors of severe cardiotoxicity in patients with severe aplastic anaemia after haploidentical haematopoietic stem cell transplantation

Regenerative Fuel Cell RFC Global Market Research and Forecast, 20152025 [Report Updated: 01011970] Prices from USD $2200

SummaryThe Regenerative Fuel Cell RFC report provides an independent information about the Regenerative Fuel Cell RFC industry supported by extensive research on factors such as industry segmentssize trends, inhibitors, dynamics, drivers, opportunities challenges, environment policy, cost overview, porter's five force analysis, and key companies profiles including business overview and recent...

Ubiquitination of MAP1LC3B by pVHL is associated with autophagy and cell death in renal cell carcinoma

Dr. Srini Pillay, Best-Selling Author, Examines the Plight of Millennials

“Many of my clients who fall into the same age group as millennials are lost, overwhelmed, confused about their careers, and lonelier than ever.” – Dr. Srini Pillay BOSTON (PRWEB) March 22, 2019 Dr. Srini Pillay, a best-selling author, neuroscientist, tech entrepreneur and an assistant professor at Harvard University, has spent a large chunk of his career subverting ideas on creativity and ...

At #CGDay19, panelists say the ability of cell and #genetherapy companies to raise capital hinges on how well they address #manufacturing and address medical needs beyond #Cancer: http://ow.ly/M9UN30o9qYS 

At #CGDay19, panelists say the ability of cell and #genetherapy companies to raise capital hinges on how well they address #manufacturing and address medical needs beyond #Cancer: http://ow.ly/M9UN30o9qYS 

WuXi AppTec Reports Strong 2018 Annual Results

Revenue RMB9,614 Million, up 23.8% (25.4% at Constant Exchange Rate) Year-Over-Year Net Profit Attributable to Owners of the Company RMB2,261 Million, up 84.2% Year-Over-Year Diluted EPS RMB 2.21, up 70.0% Year-Over-Year SHANGHAI, March 22, 2019 /PRNewswire/ -- WuXi AppTec Co., Ltd. (stock code: 603259.SH / 0235...

EU Approval Sought for Frontline Daratumumab/Rd in Transplant-Ineligible Myeloma

A Type II variation application has been submitted to the European Medicines Agency for the combination of daratumumab with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.

Sanofi: FDA issues Complete Response Letter for Zynquista(TM) (sotagliflozin)

FDA issues Complete Response Letter for Zynquista(TM) (sotagliflozin) PARIS and THE WOODLANDS, TX -  March 22, 2019 -  The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application for investigational Zynquista(TM) (sotagliflozin)*, a dual SGLT1 and SGLT2 inhibitor for the treatment of adults with type 1 diabetes in combi...

FDA rejects Sanofi, Lexicon's Zynquista for type 1 diabetes https://www.firstwordpharma.com/node/1630997?tsid=28®ion_id=6 …

FDA rejects Sanofi, Lexicon's Zynquista for type 1 diabetes https://www.firstwordpharma.com/node/1630997?tsid=28&region_id=6 …

Must-Reads Of The Week (Some Flying Below The Radar)

Executive editor Damon Darlin takes a spin as host of “The Friday Breeze,” whirling through a week of health care news so you don’t have to.

Finance Watch: Flagship Raises $824m To Speed Growth Of Its Portfolio Companies

Private Company Edition: The VC firm and start-up factory Flagship Pioneering brings in new cash for existing investments, tapping into...    

FDA Turns Down Sotagliflozin for Type 1 Diabetes

Advisory panel had expressed major concerns about diabetic ketoacidosis. Medscape Medical News

AUDIO: Podcast: Gottlieb Addresses LDT Legislation At Brookings

US FDA Commissioner Scott Gottlieb spoke with Medtech Insight about the agency’s decision to put the LDT issue to Congress...   

bluebird bio Opens State-of-the-Art Gene and Cell Therapy Manufacturing Facility

bluebird bio (NASDAQ:BLUE) has announced the opening of its first wholly owned manufacturing facility in Durham, North Carolina, which will produce lentiviral vector for its investigational gene and cell therapies. As quoted in the press release: Gov. Roy Cooper, Secretary of Commerce Tony Copeland and local patient advocates will join chief bluebird Nick Leschly in … Continued The post

Sunesis Pharmaceuticals (SNSS) - First signs of efficacy coming up

Edison Investment Research - Pharmaceuticals & healthcare - Sunesis Pharmaceuticals: Sunesis is currently in the dose-escalation portion of the Phase Ib/II study of its BTK inhibitor vecabrutinib, and the first signs of clinical efficacy are expected in the upcoming doses. The drug is being tested in a range of B-cell malignancies where BTK inhibitors have historically shown some activity. The com...

Summary of opinion: Innovax-ND-IBD,cell-associated live recombinant turkey herpesvirus expressing the fusion protein of ND virus and the VP2 protein of IBD virus, 21/03/2019, Positive

Summary of opinion: Innovax-ND-IBD,cell-associated live recombinant turkey herpesvirus expressing the fusion protein of ND virus and the VP2 protein of IBD virus, 21/03/2019, Positive

resTORbio Announces Closing Public Offering of Common Stock

resTORbio (NASDAQ:TORC) has announced the closing of a previously announced underwritten public offering of 7.2 million shares of its common stock at a price of US$6.95 per share. As quoted in the press release:  resTORbio also granted the underwriters a 30-day option to purchase up to an additional 1,080,000 shares of common stock at the … Continued The post resTORbio Announces Closing Pub...

Plus Products Inc: California Cannabis Edibles Company with Amazing Potential

Plus Products Inc Takes Stronghold in World's Largest Cannabis Market If there's any cannabis company that could do with a name change, it's Plus Products Inc (OTCMKTS:PLPRF, CNSX:PLUS). Despite a ...

It takes two: ‘No clinical AI solution can work on its own’

Clinical AI, no matter how sophisticated, cannot work on its own, says Life Image CEO, who predicts that CROs will either adapt or be disrupted by smaller companies with digital access capabilities.

Unfinished Business: LDT Legislation A Top Priority For Departing FDA Chief Gottlieb

In a farewell talk at the Brookings Institution, outgoing US FDA Commissioner Scott Gottlieb said a top unfinished business that...   

Revolutions: The Incredible Potential of Induced Pluripotent Stem Cells

(New Atlas) – Thirteen years on, Yamanaka has earned a Nobel Prize in Physiology or Medicine for his discovery (jointly award to him and Sir John B. Gurdon in 2012), and scientists have built on his work and tweaked his … Read More


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks